The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the total global prevalence of MAFLD in HCC cohorts (total-MAFLD), including the proportion with MAFLD as their sole liver disease (single-MAFLD), and the proportion of those with concurrent liver disease where MAFLD was a contributary factor (mixed-MAFLD).

中文翻译：

---

MAFLD 相关肝细胞癌的全球患病率：系统评价和荟萃分析。

代谢功能障碍相关脂肪肝病 (MAFLD) 导致的肝细胞癌 (HCC) 的全球比例尚不清楚。 MAFLD 诊断标准允许在存在脂肪变性加上明确的代谢功能障碍标志物的情况下进行客观诊断，无论是否并发肝病。我们的目的是确定 HCC 队列中 MAFLD 的全球总患病率（总 MAFLD），包括以 MAFLD 作为唯一肝病的比例（单 MAFLD），以及以 MAFLD 为促成因素的并发肝病患者的比例（混合MAFLD）。